Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results

Autor: Luis M. Ruilope, Takashi Wada, Robert D. Toto, Stefan D. Anker, George L. Bakris, Markus F. Scheerer, Gerasimos Filippatos, Ike Ogbaa, Guillermo E. Umpierrez, John Boletis, Peter Rossing, Luke Roberts, Rajiv Agarwal, Charlie Scott, Bertram Pitt, Amer Joseph, Christoph Wanner

Publikováno v: Agarwal, R, Anker, S D, Filippatos, G, Pitt, B, Rossing, P, Ruilope, L M, Boletis, J, Toto, R, Umpierrez, G E, Wanner, C, Wada, T, Scott, C, Joseph, A, Ogbaa, I, Roberts, L, Scheerer, M F, Bakris, G L & FIDELIO-DKD Investigators 2022, ' Effects of canagliflozin versus finerenone on cardiorenal outcomes : exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results ', Nephrology Dialysis Transplantation, pp. 1261–1269 . https://doi.org/10.1093/ndt/gfab336
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)

Background The nonsteroidal mineralocorticoid receptor antagonist finerenone and the sodium–glucose cotransporter-2 inhibitor (SGLT-2i) canagliflozin reduce cardiorenal risk in albuminuric patients with chronic kidney disease (CKD) and type 2 diabe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e400ea7a747a6851be755132c19f57c
https://hdl.handle.net/11268/10567

Importance of trial design when investigating cardiorenal outcomes in patients with CKD and T2D: Focus on CREDENCE and FIDELIO-DKD

Autor: Charlie Scott, Luke Ro, Amer Joseph, Peter Rossing, John Boletis, Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Takashi Wada, Christoph Wanner, Robert D. Toto, Guillermo E. Umpierrez, Stefan D. Anker, Ike Ogbaa, Luis M. Ruilope

Publikováno v: American Heart Journal. 242:162

Background Recent trials investigating novel therapies in chronic kidney disease (CKD) and type 2 diabetes (T2D) include the randomized, placebo-controlled phase III FIDELIO-DKD and CREDENCE studies of finerenone (selective, nonsteroidal mineralocort

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8940caa0ac6d5a1cf516dcaba71f695f
https://doi.org/10.1016/j.ahj.2021.10.043

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Autor: John A. Stewart, Stephan Jacob, Ike Ogbaa, Michael E. Trautmann, Richard E. Pratley, Kun-Ho Yoon, Christopher H. Sorli, Jahoon Kang, Oakpil Han, Marcus Hompesch

Publikováno v: Diabetes. 68

Once-weekly (QW) subcutaneous efpeglenatide (efpeg) is a long-acting GLP-1 RA being developed to improve glycemic control in patients with T2D. In the BALANCE 205 study (NCT02075281) in patients with obesity (median BMI 34.9 [28.1−57.7] kg/m2) with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc6691877d13da5216f909b2b46c2ee2
https://doi.org/10.2337/db19-1001-p

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

Autor: Kun-Ho Yoon, Stephan Jacob, Jahoon Kang, Christopher H. Sorli, John A. Stewart, Ike Ogbaa, Michael E. Trautmann, Richard E. Pratley, Oakpil Han, Marcus Hompesch

Publikováno v: Diabetes. 68

Once-weekly (QW), subcutaneous efpeglenatide (efpeg) is a long-acting GLP-1 RA being developed to improve glycemic control in T2D. In the 20-week BALANCE 205 study (NCT02075281), all doses of efpeg led to significant reductions in body weight (BW) vs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5349a19064b54de5b11845accd368149
https://doi.org/10.2337/db19-53-or

Study Design and Rationale of a Dose-Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

Autor: Brian Zambrowicz, Phillip Banks, William T. Cefalu, Michael R. Kelly, David R. Powell, Kenny Frazier, Arthur T. Sands, Pablo Lapuerta, Joel Freiman, Julio Rosenstock, Ike Ogbaa

Publikováno v: Clinical Cardiology. 36:367-371

Sodium-glucose cotransporters 1 (SGLT1) and 2 (SGLT2) are the major cellular transporters responsible for gastrointestinal (GI) glucose absorption and renal glucose reabsorption, respectively. LX4211, a dual inhibitor of SGLT1 and SGLT2, reduces gluc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7421fa50df9b3afe7555038aed6e9196
https://doi.org/10.1002/clc.22125